Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 3
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
3| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 9458195 | IMCIVREEsetmelanotide acetate | substance, product | Oct 2027 |
| 8039435 | IMCIVREEsetmelanotide acetate | substance, product | Aug 2032 |
| 11129869 | IMCIVREEsetmelanotide acetate | product | Jul 2034 |
| Product | Exclusivity | Until |
|---|---|---|
| IMCIVREESETMELANOTIDE ACETATE | ODE-508 Orphan drug | Dec 2031 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Imcivree | setmelanotide | solution, subcutaneous | 72829-010NDA |
Enquiry
Common questions
- Is Rhythm Pharmaceuticals, Inc FDA approved?
- Rhythm Pharmaceuticals, Inc holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Rhythm Pharmaceuticals, Inc make?
- 1 product is listed under Rhythm Pharmaceuticals, Inc in the openFDA NDC Directory, most often as solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.